Telephone
61.2.8051.3043
Address
Level 36, Gateway 1 Macquarie Place Sydney, New South Wales (NSW) 2000
Description
Race Oncology Ltd. is a clinical stage biotechnology company, which engages in the discovery and development of a novel approach to cancer treatment and cardio protection. The firm is involved in developing Bisantrene, a small molecule anthracene chemotherapeutic, to address the unmet need of patients across multiple oncology indications, with an initial focus on metastatic breast cancer and acute myeloid leukemia. It is also investigating the impact Bisantrene and new molecules have on the m6A RNA pathway. The company was founded on February 15, 2011 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.75 - 2.38
Trade Value (12mth)
AU$54,877.00
1 week
-9.57%
1 month
-7.1%
YTD
-56.96%
1 year
-63.68%
All time high
4.23
EPS 3 yr Growth
70.900%
EBITDA Margin
N/A
Operating Cashflow
-$11m
Free Cash Flow Return
-34.60%
ROIC
-32.20%
Interest Coverage
N/A
Quick Ratio
20.40
Shares on Issue (Fully Dilluted)
163m
HALO Sector
Healthcare
Next Company Report Date
23-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.01
Date | Announcements |
---|---|
31 March 22 |
Preclinical & Clinical Programs Update
×
Preclinical & Clinical Programs Update |
31 July 23 |
Quarterly Activity Report & Appendix 4C
×
Quarterly Activity Report & Appendix 4C |
31 January 23 |
Quarterly Activity Report & Appendix 4C
×
Quarterly Activity Report & Appendix 4C |
31 January 22 |
Appointment of Chief Financial Officer
×
Appointment of Chief Financial Officer |
31 August 22 |
Update - Notification of buy-back - RAC
×
Update - Notification of buy-back - RAC |
30 September 22 |
Notification of cessation of securities - RAC
×
Notification of cessation of securities - RAC |
30 November 20 |
Race AGM presentations and strategic update
×
Race AGM presentations and strategic update |
30 March 22 |
Supply Agreement for EMD AML Trial
×
Supply Agreement for EMD AML Trial |
30 June 22 |
Zantrene Protects Mouse Hearts from Chemotherapy Damage
×
Zantrene Protects Mouse Hearts from Chemotherapy Damage |
30 August 23 |
Appendix 4E & Annual Report
×
Appendix 4E & Annual Report |
30 August 23 |
Corporate Governance Statement
×
Corporate Governance Statement |
30 August 23 |
Appendix 4G
×
Appendix 4G |
30 August 22 |
Update - Notification of buy-back - RAC
×
Update - Notification of buy-back - RAC |
29 October 20 |
Annual Report to Shareholders
×
Annual Report to Shareholders |
29 November 23 |
New Zealand Investor Information
×
New Zealand Investor Information |
29 November 23 |
Notification regarding unquoted securities - RAC
×
Notification regarding unquoted securities - RAC |
29 June 23 |
Race Board Changes
×
Race Board Changes |
29 June 23 |
Final Director's Interest Notice
×
Final Director's Interest Notice |
29 June 23 |
Initial Director's Interest Notice
×
Initial Director's Interest Notice |
29 June 23 |
Proposed issue of securities - RAC
×
Proposed issue of securities - RAC |
29 June 23 |
Notification of cessation of securities - RAC
×
Notification of cessation of securities - RAC |
28 September 22 |
Race Develops Improved IV Formulation of Zantrene
×
Race Develops Improved IV Formulation of Zantrene |
28 September 18 |
Notification of 2018 Annual General Meeting Date
×
Notification of 2018 Annual General Meeting Date |
28 June 22 |
Zantrene shows synergy with kinase inhibitors in melanoma
×
Zantrene shows synergy with kinase inhibitors in melanoma |
28 July 22 |
Update - Notification of buy-back - RAC
×
Update - Notification of buy-back - RAC |
28 January 22 |
Quarterly Activity Report & Appendix 4C
×
Quarterly Activity Report & Appendix 4C |
28 April 23 |
Quarterly Activity Report & Appendix 4C
×
Quarterly Activity Report & Appendix 4C |
27 September 23 |
Bisantrene cGMP API Manufacturing Completed at Laurus Labs
×
Bisantrene cGMP API Manufacturing Completed at Laurus Labs |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.